Compositions comprising a tissue glue and therapeutic agents

a tissue glue and therapeutic agent technology, applied in the field of medical therapies, can solve the problems of difficult to apply localised therapy over a surface rather than at a single point, and the means for achieving this end have been extremely limited, so as to achieve the effect of reducing the exposure of surgeons and operating sta

Inactive Publication Date: 2005-01-06
FILLER AARON GERSHON +1
View PDF26 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] In a broad aspect of the invention, a ferrite or other radiotherapeutic agent, in particulate form, is suspended in a tissue glue, suitably in the pre-mix. If a colloidal solution of, say, β-emitting ferrite is prepared in a tissue glue, this can be applied after surgical resection of a tumour, particularly near an eloquent area of the brain, where a thin shell of tumour may remain, minimising exposure to the surgeon and operating staff. The particles are biodegradable, and so will be resorbed over weeks. A cell adhesion moiety-coupled radionuclide may be used, if the agent is not physically held in the matrix.

Problems solved by technology

There are a number of problems in medicine for which therapy requires direct physical placement of a treating agent.
However, the means for achieving this end are extremely limited and this end has seemed to be extraordinarily difficult to achieve.
It is sometimes possible to place a bead, capsule or seed with an agent at a given location, but it is very difficult to apply such localised therapy over a surface rather than at a single point.
One such problem, well known to surgeons who specialise in the treatment of brain cancer (e.g. gliomas), arises because tumour cells infiltrate into the otherwise normal brain surrounding a gross tumour.
However, even very toxic agents which cause severe toxic side-effects throughout the body have only a very slight slowing effect on tumour cell growth of gliomas.
Radiation therapy may be given but, in young children, the radiation causes grievous harm to the surrounding brain and, in adults as well, there is risk of severe scarring from the radiation which can cause swelling and mass effects in large regions of the brain.
Although radiation clearly slows the growth of the tumour, it is virtually impossible to deliver enough radiation to slow the tumour substantially without causing unacceptable damage to the brain.
Results for treatment of brain cancer remain dismal, and life expectancy after diagnosis is measured in months with or without surgery.
These catheters cause a risk of infection spreading along the catheter and do not provide a uniform field of radiation and are not well suited for treating the surface of the tumour resection bed in the brain.
The problem with this current method is that the painstaking process of gluing on the seeds requires as much as an hour during which time the full operating room team (surgeon, assistant surgeon, radiation therapy treatment planner, radiation therapy technician, anaesthesiologist, scrub nurse, circulating nurse) are all required to be present and are all subject to unshielded radiation exposure.
It is not possible to suspend the seeds in either a liquid cyanoacrylate glue or in either component of a tissue glue as described above, because they would sink out of solution.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising a tissue glue and therapeutic agents
  • Compositions comprising a tissue glue and therapeutic agents
  • Compositions comprising a tissue glue and therapeutic agents

Examples

Experimental program
Comparison scheme
Effect test

example

[0076] Add 1.5 ml of 33% NH3 to 4.5 ml of hot dH2O (to make up 7.5% NH4OH) and leave standing in a capped universal tube in the water bath and bring to 60° C.

[0077] Dissolve 1.25 grams of Dextran (MW 10,000) in 2.0 ml of ddH2O then dissolve 225 mg FeCl3.6H2O in the dextran solution. Other macromolecules such as proteins, fibrin, collagen, starch, polylysine, or derivatized dextrans may also be used for the coating. Alternatively, a trivalent lanthanide or Group IIIB chloride may be substituted for 10-50% of the FeCl3. A variety of unstable isotopes of various transition, lanthanide and actinide elements can be introduced at this step as metal chlorides dissolved in water or in an acidic solution of e.g. 0.1M HCl. The amount of trivalent iron may be reduced where trivalent cations are added.

[0078] Dissolve 100 mg FeCl2.4H2O in the Fe3 / dextran solution then place the mixture in a 60° C. water bath for two minutes. Some divalent cations may be added in place of Fe at this step. Some ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
surface areaaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This is a continuation-in-part of U.S. application Ser. No 07 / 988,919, filed May 4, 1993.FIELD OF THE INVENTION [0002] This invention is in the field of medical therapeutics and concerns novel means of delivering therapeutic agents. In particular, this concerns percutaneous or surgical application of therapeutic agents which are intended to remain at or near the location at which they are placed by the treating physician or surgeon. BACKGROUND OF THE INVENTION [0003] There are a number of problems in medicine for which therapy requires direct physical placement of a treating agent. However, the means for achieving this end are extremely limited and this end has seemed to be extraordinarily difficult to achieve. [0004] It is often possible to deliver a drug to a specific location, such as by the injection of local anaesthetic near a nerve which must be numbed. However, most small molecules will diffuse away from their injection site, or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61K47/42A61K51/12A61L24/00
CPCA61K9/0019A61K9/0024A61K47/42A61K51/1213A61L2300/44A61L24/0015A61L2300/102A61L2300/414A61K2121/00
Inventor FILLER, AARON GERSHONLINDSAY LEVER, ANDREW MICHAEL
Owner FILLER AARON GERSHON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products